Spark Therapeutics, Inc. (ONCE) Now Covered by Analysts at Royal Bank Of Canada
Stock analysts at Royal Bank Of Canada initiated coverage on shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) in a research report issued to clients and investors on Thursday, The Fly reports. The firm set an “outperform” rating on the biotechnology company’s stock.
Other equities analysts have also issued research reports about the company. Jefferies Group LLC reaffirmed a “buy” rating and set a $95.00 price objective (up previously from $85.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Evercore ISI began coverage on Spark Therapeutics in a report on Wednesday, August 16th. They set an “in-line” rating and a $83.00 price objective on the stock. Zacks Investment Research raised Spark Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 19th. Chardan Capital reaffirmed a “neutral” rating on shares of Spark Therapeutics in a report on Monday, July 24th. Finally, BidaskClub raised Spark Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $83.77.
Spark Therapeutics (NASDAQ ONCE) traded down 0.54% during mid-day trading on Thursday, reaching $81.27. The company’s stock had a trading volume of 322,399 shares. The firm’s market cap is $2.54 billion. The stock’s 50 day moving average is $82.71 and its 200 day moving average is $69.14. Spark Therapeutics has a one year low of $35.07 and a one year high of $85.26.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.75) by ($0.14). The firm had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.04) EPS. On average, analysts anticipate that Spark Therapeutics will post ($7.69) EPS for the current year.
In other Spark Therapeutics news, CFO Stephen W. Webster sold 2,337 shares of Spark Therapeutics stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $71.12, for a total value of $166,207.44. Following the sale, the chief financial officer now owns 4,837 shares of the company’s stock, valued at approximately $344,007.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Katherine A. High sold 10,000 shares of Spark Therapeutics stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $60.00, for a total value of $600,000.00. Following the completion of the sale, the insider now directly owns 220,000 shares in the company, valued at approximately $13,200,000. The disclosure for this sale can be found here. Insiders sold a total of 374,160 shares of company stock worth $26,723,411 in the last ninety days. 7.30% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in ONCE. Teachers Advisors LLC boosted its holdings in Spark Therapeutics by 16.8% in the 4th quarter. Teachers Advisors LLC now owns 33,884 shares of the biotechnology company’s stock valued at $1,691,000 after purchasing an additional 4,875 shares in the last quarter. Nationwide Fund Advisors lifted its position in shares of Spark Therapeutics by 2.5% during the 1st quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock valued at $923,000 after acquiring an additional 414 shares during the period. Wells Fargo & Company MN lifted its position in shares of Spark Therapeutics by 131.8% during the 1st quarter. Wells Fargo & Company MN now owns 522,894 shares of the biotechnology company’s stock valued at $27,891,000 after acquiring an additional 297,277 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Spark Therapeutics by 10.9% during the 1st quarter. Bank of New York Mellon Corp now owns 111,043 shares of the biotechnology company’s stock valued at $5,923,000 after acquiring an additional 10,916 shares during the period. Finally, TD Asset Management Inc. lifted its position in shares of Spark Therapeutics by 4.5% during the 1st quarter. TD Asset Management Inc. now owns 76,451 shares of the biotechnology company’s stock valued at $4,078,000 after acquiring an additional 3,300 shares during the period. 91.01% of the stock is currently owned by institutional investors.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.